Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Breast Neoplasms 251Lymphoma 241Precursor Cell Lymphoblastic Leukemia-Lymphoma 192Leukemia 178Lymphoma, Large B-Cell, Diffuse 167Multiple Myeloma 166Lymphoma, Non-Hodgkin 155Leukemia, Lymphocytic, Chronic, B-Cell 146Leukemia, Myeloid, Acute 136Myelodysplastic Syndromes 116Hodgkin Disease 115Lymphoma, Follicular 113Burkitt Lymphoma 108Lymphoma, Mantle-Cell 104Lymphoma, B-Cell, Marginal Zone 76Lymphoma, Large-Cell, Immunoblastic 64Neoplasms, Plasma Cell 59Recurrence 58Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57Myeloproliferative Disorders 53Neoplasms 49Leukemia, Myeloid, Chronic-Phase 49Triple Negative Breast Neoplasms 47Leukemia, Myeloid, Accelerated Phase 47Melanoma 46Leukemia, Myelomonocytic, Chronic 46Dendritic Cell Sarcoma, Interdigitating 46Waldenstrom Macroglobulinemia 42Hematologic Neoplasms 41Congenital Abnormalities 39

Interventions

Denosumab 3gentamicin-polymethylmethacrylate bead 1fludarabine 1aldesleukin 1Zoledronic Acid 1Vitamin D 1Nivolumab 1Ipilimumab 1Dasatinib 1Cyclophosphamide 1Calcium 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Giant Cell Tumor of Bone × Cyclophosphamide × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡